secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001628280-24-042630
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers
--------------------------------------------------------------------------------

- First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.
- Primary target patient population is non-small cell lung cancer (NSCLC).
- Lilly leads clinical development under a U.S. 50/50 co-development and co-commercialization collaboration with Foghorn.
- Preclinical studies showed robust anti-tumor monotherapy activity and favorable tolerability in SMARCA2 mutant xenograft models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/0001628280-24-042630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/fhtx-20241010.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer